Phase 2 Crohn's Disease and Colitis Trial, RecruitingNCT06226883Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)Condition: Crohn's Disease and Colitis
Printed from Voxsanity (voxsanity.com.au) — NCT06226883 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Phase 2 Crohn's Disease and Colitis Trial, Recruiting
NCT06226883
RecruitingPhase 2🇦🇺 Australian site
voxsanity.com.au ·
Eligibility summary from public government registries ·
18 August 2026 ·
not medical advice
Who may and may not be able to join
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who may be able to join
You have had signs or symptoms of Crohn's disease (CD) for at least 90 days before the screening visit.
Your Crohn's disease is considered moderately to severely active, based on a specific scoring system called the CDAI (with a score between 220 and 450), and you have frequent loose stools and/or significant abdominal pain on a daily basis.
A camera examination of your gut (such as a colonoscopy) shows a certain level of active inflammation, based on a scoring system called the SES-CD (confirm with trial site for exact score details).
Previous treatments for Crohn's disease have not worked well enough for you, stopped working over time, or caused side effects you could not tolerate — this includes steroids, medications that suppress the immune system (such as azathioprine, 6-mercaptopurine, or methotrexate), or more advanced treatments like biologic medicines or JAK inhibitors.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
You have been diagnosed with a different type of bowel condition, such as ulcerative colitis, microscopic colitis, ischemic colitis, or radiation colitis, or your symptoms suggest you might have ulcerative colitis.
Your Crohn's disease only affects certain parts of the digestive tract (such as the mouth, stomach, or the area around the back passage), without involving the large or small intestine.
You have had a large section of your bowel removed (more than 100 cm), more than 3 bowel surgeries, or have been diagnosed with short bowel syndrome.
You are currently being fed through a tube or a drip directly into a vein (intravenous nutrition), or are on a liquid-only formula diet.
You have certain concerns flagged on a neurological (brain and nerve) screening questionnaire (confirm with trial site).
You have another serious or unstable health condition alongside your Crohn's disease.
You have previously been treated with a medicine called vedolizumab or any similar type of drug known as an integrin inhibitor.
You are currently taking part in another clinical trial, or have received an experimental treatment within the last 30 days.
You have previously been given the study drug (MORF-057), or you are known to be allergic or sensitive to drugs that work in a similar way.
You are unable to attend the required study visits or follow the study procedures.
You have a history of a major neurological condition, such as a stroke, multiple sclerosis, a brain tumour, or a disease affecting the nerves or brain.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Contact this trial
Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Southern Adelaide Local Health Network, Bedford Park,
+61 (8) 8204 4964
Royal Brisbane and Women's Hospital, Herston,
+61 (7) 3646 4273
IBD SA SA Group of Specialists, Kurralta Park,
The Alfred Hospital, Melbourne,
+61 (03) 9076 8838
St. Vincent's Hospital, Melbourne,
+61 (3) 92313580
Royal Perth Hospital, Perth,
Sir Charles Gairdner Hospital, Perth,
+61 (0) -8645-7367
Princess Alexandra Hospital, Metro South Health, Woolloongabba, QLD,
61731767792
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT06226883
Sponsor: Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Phase: Phase 2
Status: Recruiting
Condition: Crohn's Disease and Colitis
Trial contact: 1-317-615-4559
More information: https://clinicaltrials.gov/study/NCT06226883
Eligibility summary (AI generated)
Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who may be able to join
You have had signs or symptoms of Crohn's disease (CD) for at least 90 days before the screening visit.
Your Crohn's disease is considered moderately to severely active, based on a specific scoring system called the CDAI (with a score between 220 and 450), and you have frequent loose stools and/or significant abdominal pain on a daily basis.
A camera examination of your gut (such as a colonoscopy) shows a certain level of active inflammation, based on a scoring system called the SES-CD (confirm with trial site for exact score details).
Previous treatments for Crohn's disease have not worked well enough for you, stopped working over time, or caused side effects you could not tolerate — this includes steroids, medications that suppress the immune system (such as azathioprine, 6-mercaptopurine, or methotrexate), or more advanced treatments like biologic medicines or JAK inhibitors.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
You have been diagnosed with a different type of bowel condition, such as ulcerative colitis, microscopic colitis, ischemic colitis, or radiation colitis, or your symptoms suggest you might have ulcerative colitis.
Your Crohn's disease only affects certain parts of the digestive tract (such as the mouth, stomach, or the area around the back passage), without involving the large or small intestine.
You have had a large section of your bowel removed (more than 100 cm), more than 3 bowel surgeries, or have been diagnosed with short bowel syndrome.
You are currently being fed through a tube or a drip directly into a vein (intravenous nutrition), or are on a liquid-only formula diet.
You have certain concerns flagged on a neurological (brain and nerve) screening questionnaire (confirm with trial site).
You have another serious or unstable health condition alongside your Crohn's disease.
You have previously been treated with a medicine called vedolizumab or any similar type of drug known as an integrin inhibitor.
You are currently taking part in another clinical trial, or have received an experimental treatment within the last 30 days.
You have previously been given the study drug (MORF-057), or you are known to be allergic or sensitive to drugs that work in a similar way.
You are unable to attend the required study visits or follow the study procedures.
You have a history of a major neurological condition, such as a stroke, multiple sclerosis, a brain tumour, or a disease affecting the nerves or brain.
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
Trial details
Status
Recruiting
Phase
Phase 2
Sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Registry
ClinicalTrials.gov
Start date
18 July 2024
Est. completion
1 September 2028
Where this trial is recruiting
🇦🇺 Australia
🇦🇹 Austria
Bosnia and Herzegovina
🇧🇷 Brazil
🇧🇬 Bulgaria
🇨🇦 Canada
🇨🇴 Colombia
🇭🇷 Croatia
🇨🇿 Czechia
🇪🇪 Estonia
🇫🇷 France
🇬🇪 Georgia
🇩🇪 Germany
🇭🇺 Hungary
🇮🇳 India
🇮🇹 Italy
🇯🇵 Japan
🇰🇿 Kazakhstan
🇱🇻 Latvia
🇲🇽 Mexico
Moldova
🇵🇱 Poland
🇷🇴 Romania
🇷🇸 Serbia
🇸🇰 Slovakia
🇪🇸 Spain
🇹🇼 Taiwan
🇺🇸 United States
8 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Proportion of participants with endoscopic response at Week 14 as determined using the Simple Endoscopic Score-CD (SES-CD)
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.
Analytics cookies are set only if you accept. Advertising runs with personalisation
permanently off and is not changed by this choice — see our
Privacy Policy.